# Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

> **NCT02929576** · PHASE3 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02929576
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2019-04
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Further understanding about the role of androgen signaling in TNBC was required
- **Last updated:** 2018-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929576, "Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02929576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*